PARP inhibitor olaparib and anti-VEGF bevacizumab - targeted treatment and efforts to improve the outcome of patients with advanced tuboovarian cancer
2020
Abstract
In the Czech Republic, approximately 1,000 women are diagnosed annually with malignant neoplasm of the ovaries (C56) and 600-700 of them die of this diagnosis. High-grade serous carcinoma is a major malignancy within this group, unfortunately often found already in advanced stages of the disease.
Surgical therapy with an ideal R0 resection and carboplatin+paclitaxel chemotherapy are essential components of cancer treatment. However, recently available target therapy molecules - bevacizumab (anti-VEGF - vascular endothelial growt factor) and "younger" olaparib (PARP inhibitor - poly-ADP-ribozo polymerase) - have added another significant effect to the treatment.